Journal article

Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial

Gillian M Duchesne, Henry H Woo, Julie K Bassett, Steven J Bowe, Catherine D'Este, Mark Frydenberg, Madeleine King, Leo Ledwich, Andrew Loblaw, Shawn Malone, Jeremy Millar, Roger Milne, Rosemary G Smith, Nigel Spry, Martin Stockler, Rodney A Syme, Keen Hun Tai, Sandra Turner

LANCET ONCOLOGY | ELSEVIER SCIENCE INC | Published : 2016

Abstract

BACKGROUND: Androgen-deprivation therapy is offered to men with prostate cancer who have a rising prostate-specific antigen after curative therapy (PSA relapse) or who are considered not suitable for curative treatment; however, the optimal timing for its introduction is uncertain. We aimed to assess whether immediate androgen-deprivation therapy improves overall survival compared with delayed therapy. METHODS: In this randomised, multicentre, phase 3, non-blinded trial, we recruited men through 29 oncology centres in Australia, New Zealand, and Canada. Men with prostate cancer were eligible if they had a PSA relapse after previous attempted curative therapy (radiotherapy or surgery, with or..

View full abstract

Grants

Awarded by Australian National Health and Medical Research Council and Cancer Councils


Funding Acknowledgements

Cancer Council Victoria sponsored the trial. The trial was supported by peer-reviewed grants from the Australian National Health and Medical Research Council and Cancer Councils (number 350201), The Royal Australian and New Zealand College of Radiologists, and by an educational grant from Mayne Pharma Australia (now part of the Pfizer group). We thank the trial coordinating and contributing centres' staff, the statisticians who have previously guided the trial, and the patients who entered the study.